Kura Oncology (KURA) Competitors

$9.29 +0.04 (+0.43%)

Closing price 04:00 PM Eastern

Extended Trading

$9.20 -0.09 (-0.97%)

As of 05:18 PM Eastern

KURA vs. KNSA, GPCR, RCUS, ALMS, and DNLI

Should you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Kiniksa Pharmaceuticals International (KNSA), Structure Therapeutics (GPCR), Arcus Biosciences (RCUS), Alumis (ALMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Kura Oncology compare to Kiniksa Pharmaceuticals International?

Kura Oncology (NASDAQ:KURA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

: Kura Oncology presently has a consensus price target of $26.38, indicating a potential upside of 183.91%. Kiniksa Pharmaceuticals International has a consensus price target of $60.86, indicating a potential upside of 7.26%. Given Kura Oncology's stronger consensus rating and higher possible upside, research analysts clearly believe Kura Oncology is more favorable than Kiniksa Pharmaceuticals International.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
1 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
Kiniksa Pharmaceuticals International
1 Sell rating(s)

1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.67
: Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Kura Oncology's net margin of -412.95%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Kura Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Kura Oncology -412.95% -102.59% -39.61%
Kiniksa Pharmaceuticals International 9.69% 13.26% 9.86%
: In the previous week, Kiniksa Pharmaceuticals International had 30 more articles in the media than Kura Oncology. MarketBeat recorded 35 mentions for Kiniksa Pharmaceuticals International and 5 mentions for Kura Oncology. Kiniksa Pharmaceuticals International's average media sentiment score of 0.66 beat Kura Oncology's score of 0.41 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kura Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kiniksa Pharmaceuticals International
14 Very Positive mention(s)
6 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 53.5% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Kiniksa Pharmaceuticals International has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology $67.48M 12.22 -$278.67M -$3.18 N/A
Kiniksa Pharmaceuticals International $754.05M 5.76 $59.01M $0.90 63.04
: Kura Oncology has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Kiniksa Pharmaceuticals International	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-412.95%	-102.59%	-39.61%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	14 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.22	-$278.67M	-$3.18	N/A
Kiniksa Pharmaceuticals International	$754.05M	5.76	$59.01M	$0.90	63.04

Summary

Kiniksa Pharmaceuticals International beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Structure Therapeutics?

Kura Oncology (NASDAQ:KURA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

: 91.8% of Structure Therapeutics shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Kura Oncology presently has a consensus price target of $26.38, indicating a potential upside of 183.91%. Structure Therapeutics has a consensus price target of $109.25, indicating a potential upside of 165.82%. Given Kura Oncology's higher probable upside, equities analysts clearly believe Kura Oncology is more favorable than Structure Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
1 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
Structure Therapeutics
2 Sell rating(s)

1 Hold rating(s)

13 Buy rating(s)

3 Strong Buy rating(s)
2.89
: In the previous week, Structure Therapeutics had 4 more articles in the media than Kura Oncology. MarketBeat recorded 9 mentions for Structure Therapeutics and 5 mentions for Kura Oncology. Structure Therapeutics' average media sentiment score of 0.75 beat Kura Oncology's score of 0.41 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kura Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Structure Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Structure Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -412.95%. Structure Therapeutics' return on equity of -25.90% beat Kura Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Kura Oncology -412.95% -102.59% -39.61%
Structure Therapeutics N/A -25.90% -24.54%
: Kura Oncology has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.31, suggesting that its stock price is 231% less volatile than the S&P 500.
: Structure Therapeutics has lower revenue, but higher earnings than Kura Oncology. Structure Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology $67.48M 12.22 -$278.67M -$3.18 N/A
Structure Therapeutics N/A N/A -$141.20M -$0.79 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	3 Strong Buy rating(s)	2.89

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Structure Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-412.95%	-102.59%	-39.61%
Structure Therapeutics	N/A	-25.90%	-24.54%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.22	-$278.67M	-$3.18	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.79	N/A

Summary

Structure Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to Arcus Biosciences?

Kura Oncology (NASDAQ:KURA) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

: In the previous week, Arcus Biosciences had 1 more articles in the media than Kura Oncology. MarketBeat recorded 6 mentions for Arcus Biosciences and 5 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.41 beat Arcus Biosciences' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kura Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcus Biosciences
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Arcus Biosciences has a net margin of -142.91% compared to Kura Oncology's net margin of -412.95%. Arcus Biosciences' return on equity of -65.77% beat Kura Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Kura Oncology -412.95% -102.59% -39.61%
Arcus Biosciences -142.91% -65.77% -32.51%
: Kura Oncology has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology $67.48M 12.22 -$278.67M -$3.18 N/A
Arcus Biosciences $247M 13.27 -$353M -$3.30 N/A
: 92.9% of Arcus Biosciences shares are owned by institutional investors. 7.6% of Kura Oncology shares are owned by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Kura Oncology presently has a consensus price target of $26.38, indicating a potential upside of 183.91%. Arcus Biosciences has a consensus price target of $32.44, indicating a potential upside of 24.38%. Given Kura Oncology's stronger consensus rating and higher probable upside, equities analysts clearly believe Kura Oncology is more favorable than Arcus Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
1 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
Arcus Biosciences
1 Sell rating(s)

3 Hold rating(s)

6 Buy rating(s)

1 Strong Buy rating(s)
2.64
: Kura Oncology has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-412.95%	-102.59%	-39.61%
Arcus Biosciences	-142.91%	-65.77%	-32.51%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.22	-$278.67M	-$3.18	N/A
Arcus Biosciences	$247M	13.27	-$353M	-$3.30	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Arcus Biosciences beats Kura Oncology on 10 of the 17 factors compared between the two stocks.

How does Kura Oncology compare to Alumis?

Kura Oncology (NASDAQ:KURA) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

: Kura Oncology has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Alumis has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500.
: Kura Oncology has a net margin of -412.95% compared to Alumis' net margin of -1,011.75%. Kura Oncology's return on equity of -102.59% beat Alumis' return on equity.
Company Net Margins Return on Equity Return on Assets
Kura Oncology -412.95% -102.59% -39.61%
Alumis -1,011.75% -116.97% -88.43%
: Alumis has lower revenue, but higher earnings than Kura Oncology. Alumis is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology $67.48M 12.22 -$278.67M -$3.18 N/A
Alumis $24.05M 138.20 -$243.32M -$3.06 N/A
: In the previous week, Kura Oncology had 5 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Kura Oncology and 0 mentions for Alumis. Kura Oncology's average media sentiment score of 0.41 beat Alumis' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.
Company Overall Sentiment
Kura Oncology Neutral
Alumis Neutral
: Kura Oncology presently has a consensus price target of $26.38, indicating a potential upside of 183.91%. Alumis has a consensus price target of $38.60, indicating a potential upside of 47.72%. Given Kura Oncology's higher possible upside, equities research analysts plainly believe Kura Oncology is more favorable than Alumis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology
1 Sell rating(s)
2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
Alumis
1 Sell rating(s)

0 Hold rating(s)

10 Buy rating(s)

1 Strong Buy rating(s)
2.92

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-412.95%	-102.59%	-39.61%
Alumis	-1,011.75%	-116.97%	-88.43%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	12.22	-$278.67M	-$3.18	N/A
Alumis	$24.05M	138.20	-$243.32M	-$3.06	N/A

Company	Overall Sentiment
Kura Oncology	Neutral
Alumis	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Alumis	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Kura Oncology beats Alumis on 9 of the 14 factors compared between the two stocks.

How does Kura Oncology compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

: Kura Oncology has higher revenue and earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics N/A N/A -$512.54M -$2.97 N/A
Kura Oncology $67.48M 12.22 -$278.67M -$3.18 N/A
: In the previous week, Denali Therapeutics had 5 more articles in the media than Kura Oncology. MarketBeat recorded 10 mentions for Denali Therapeutics and 5 mentions for Kura Oncology. Denali Therapeutics' average media sentiment score of 0.91 beat Kura Oncology's score of 0.41 indicating that Denali Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Denali Therapeutics
5 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kura Oncology
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Denali Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -412.95%. Denali Therapeutics' return on equity of -50.13% beat Kura Oncology's return on equity.
Company Net Margins Return on Equity Return on Assets
Denali Therapeutics N/A -50.13% -44.20%
Kura Oncology -412.95% -102.59% -39.61%
: Denali Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 84.99%. Kura Oncology has a consensus target price of $26.38, indicating a potential upside of 183.91%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Denali Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Denali Therapeutics
1 Sell rating(s)
1 Hold rating(s)

13 Buy rating(s)

1 Strong Buy rating(s)
2.88
Kura Oncology
1 Sell rating(s)

2 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.69
: 92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Denali Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Kura Oncology has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	N/A	N/A	-$512.54M	-$2.97	N/A
Kura Oncology	$67.48M	12.22	-$278.67M	-$3.18	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-50.13%	-44.20%
Kura Oncology	-412.95%	-102.59%	-39.61%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Denali Therapeutics beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$824.61M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-2.92	38.85	29.04	28.47
Price / Sales	12.22	155.53	476.61	60.94
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	4.65	7.03	9.67	6.67
Net Income	-$278.67M	$23.62M	$3.55B	$332.53M
7 Day Performance	5.21%	3.67%	1.70%	2.01%
1 Month Performance	7.90%	7.16%	5.62%	9.20%
1 Year Performance	38.24%	67.03%	34.42%	39.59%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	2.0858 of 5 stars	$9.29 +0.4%	$26.38 +183.9%	N/A	$824.61M	$67.48M	N/A	130	Upcoming Earnings
KNSA Kiniksa Pharmaceuticals International	2.6498 of 5 stars	$43.61 +1.9%	$56.00 +28.4%	N/A	$3.27B	$677.56M	58.93	220	Earnings Report Analyst Upgrade High Trading Volume
GPCR Structure Therapeutics	2.7652 of 5 stars	$45.33 -0.4%	$109.25 +141.0%	N/A	$3.22B	N/A	N/A	136	Upcoming Earnings
RCUS Arcus Biosciences	1.8162 of 5 stars	$24.99 -2.0%	$32.44 +29.8%	N/A	$3.20B	$247M	N/A	500	Earnings Report Analyst Upgrade
ALMS Alumis	1.9773 of 5 stars	$24.75 -0.7%	$38.60 +56.0%	N/A	$3.17B	$24.05M	N/A	N/A	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. KNSA, GPCR, RCUS, ALMS, and DNLI

How does Kura Oncology compare to Kiniksa Pharmaceuticals International?

Summary

How does Kura Oncology compare to Structure Therapeutics?

Summary

How does Kura Oncology compare to Arcus Biosciences?

Summary

How does Kura Oncology compare to Alumis?

Summary

How does Kura Oncology compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. KNSA, GPCR, RCUS, ALMS, and DNLI

How does Kura Oncology compare to Kiniksa Pharmaceuticals International?

Summary

How does Kura Oncology compare to Structure Therapeutics?

Summary

How does Kura Oncology compare to Arcus Biosciences?

Summary

How does Kura Oncology compare to Alumis?

Summary

How does Kura Oncology compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools